A new era of therapy for hepatitis C virus (HCV) infection is dawning with the development of two effective HCV protease inhibitors, boceprevir and telaprevir. In this issue of the Journal, the res...
A large number of new therapies are in development for chronic hepatitis C including direct-acting antiviral drugs (DAA), which target specific hepatitis C virus enzymes. Two of these compounds hav...
PDF | Hepatitis C virus (HCV), the major etiologic agent of "non-A, non-B hepatitis" was discovered 26 years ago. Even before its discovery,... | Find, read and cite all the research you need on Re...
Worldwide, ∼170 million people are thought to be chronically infected with HCV. These patients can develop serious long-term complications. Therapy for hepatitis C has progressed rapidly in the pas...
Before scientists identified HCV in 1989, hepatitis C was called non-A, non-B hepatitis.[ 1 ] For many years, scientists recognized six major strains of HCV, or HCV genotypes, and dozens of...
Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication. by Katharina Esser-Nobis, Christian Harak, Philipp Schu...
Cryoglobulins are present in about a quarter of patients with hepatitis C; in some, cryoglobulinemia can become symptomatic or even life-threatening. This review summarizes evolving therapy for the...
Despite the great successes achieved in the fields of virology and diagnostics, several difficulties affect improvements in hepatitis C virus (HCV) infection control and eradication in the new era...
Therapy for hepatitis C is undergoing a revolution. Several new drugs against the hepatitis C virus (HCV) have reached the market and many others, including direct-acting antivirals and host-target...
Create your account to get 2 free subscriber-only articles each month. Get Free Access Now · Subscribe For Full Access ; Already have an account? · Sign In · Print subscriber? · Activate your online access.